Results 181 to 190 of about 390,856 (338)

The efficacy of Telitacicept in Childhood‐onset Systemic Lupus Erythematosus: a prospective multi‐center cohort study with IPTW‐adjusted comparison to a historical control group treated with Belimumab

Arthritis &Rheumatology, Accepted Article.
Objective The therapeutic effects of Telitacicept combined with standard of care (SoC) in childhood‐onset systemic lupus erythematosus (cSLE) remain unclear. This study aims to evaluate its efficacy in comparison with Belimumab combined with SoC. Methods We performed a prospective cohort study across 7 tertiary hospitals in China, enrolling patients ...
Chong Luo, Shu Su, Jingyue Liu, Junyu Lin, Jin Song, Zongwen Chen, Yuanyuan Peng, Lijun Jiang, Meng Jia, Li Wang, Xinhui Jiang, Wei Zhang, Zanhua Rong, Bo zhao, Yajun Wang, Xuemei Tang   +15 more
wiley   +1 more source

Koebner Phenomenon Induced by Eyeglasses in a Patient With Discoid Lupus Erythematosus. [PDF]

Case Rep Dermatol Med
Fathizadeh S, Woods AD, Haber R.
europepmc   +1 more source

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019

, 2020
Bathon, J., Breedveld, F., Burmester, G., Bykerk, V., Crofford, L., Cronstein, B., Dougados, M., Furst, D., Kalden, J., Mariette, X., Mease, P., Melchers, F., Rosenbaum, J., Sieper, J., Smolen, J., Weinblatt, M., Winthrop, K.   +16 more
core   +1 more source

HLA‐DQA1*01:02 is associated with antibody multi‐reactivity with citrulline‐containing type II collagen epitopes while HLA‐DRB1*04:01 is associated with more private antibody reactivity with citrulline‐containing IgG epitopes in rheumatoid arthritis

Arthritis &Rheumatology, Accepted Article.
Objective Anti‐citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA) can be promiscuous, with cross‐reactive binding to many antigens containing short motifs, or private with little cross‐reactivity. Also, ACPA reactivity patterns differ among RA patients, including for motif‐containing epitopes in important self‐antigens like collagen ...
S. Janna Bashar, Courtney B. Myhr, Adam H. Titi, Zihao Zheng, Miriam A. Shelef   +4 more
wiley   +1 more source

Bullous Systemic Lupus Erythematosus As the Initial Presentation of Systemic Lupus Erythematosus. [PDF]

Cureus
Kydyralieva C.
europepmc   +1 more source

Biomarkers of Lupus Nephritis Histopathology: Where Do We Stand?

Arthritis &Rheumatology, Accepted Article.
Objective Lupus nephritis (LN) is characterized by a variable disease course, necessitating continuous monitoring. There is an urgent need to identify non‐invasive biomarkers. By reviewing and critically assessing the quality of existing studies on LN biomarkers correlating with histopathology, we here explore the challenges in promoting their use in ...
Valentina Querin, Leonardo Palazzo, Agnes B. Fogo, Mark Haas, David R. W. Jayne, Liz Lightstone, Brad H. Rovin, Surya V. Seshan, Augusto Vaglio, Ioannis Parodis, Ingeborg M. Bajema, The LN classification steering committee   +11 more
wiley   +1 more source

GDF10 Regulates Iron‐Dependent Lipid Oxidation in Colorectal Cancer Cells Through Interaction With IGF2

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Background: This study aims to identify genes with a high likelihood of genetic variation, significant expression differences, and prognostic implications in colorectal cancer (CRC) patients. The research also seeks to investigate the role and mechanisms of key genes in CRC through the analysis of health information data and a combination of ...
Kaobin Ouyang, Tianying Huang, Dan Xie, Hailin Xiong   +3 more
wiley   +1 more source

A scoping review of disease‐modifying antirheumatic drug nonadherence in rheumatoid arthritis: Measurement, prevalence and implications for clinical practice

British Journal of Clinical Pharmacology, EarlyView.
Aims Adherence to disease‐modifying antirheumatic drugs (DMARDs) has been associated with improved treatment outcomes, but how adherence is reported ranges between studies. We therefore aimed to determine how nonadherence to DMARDs used to treat rheumatoid arthritis (RA) has been measured and to report the nonadherence rate with each measure identified.
Lauren Fraser, Nagham Ailabouni, Lisa Kalisch Ellett, Jiun Ming Tan, Anthea Freeman, Susanna M. Proudman, Emily Reeve, Michael D. Wiese   +7 more
wiley   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Enpatoran, a first-in-class, selective, orally administered toll-like receptor 7/8 inhibitor, in systemic and cutaneous lupus erythematosus: results from a randomised, placebo-controlled phase Ib study. [PDF]

Lupus Sci Med
Witte T, Fernandez-Ruiz R, Abramova N, Weinelt D, Moreau F, Klopp-Schulze L, Shaw J, Denis D, Wenzel J.   +8 more
europepmc   +1 more source